Dr Reddys Laboratories Ltd, has announced the inauguration of their first finished dosages plant at Visakhapatnam. With a built up area of 15.7 acres (65,000 sq mts), the plant is ecologically balanced with a beautiful green belt covering 8 acres of surrounding land. This plant is the seventh finished dosage facility of the company. The last facility was inaugurated in March 2006, at Baddi, Himachal Pradesh.
The state of the art plant is specially designed to manufacture a broad range of products including Cytotoxic and Anti-hormonal products, and injectibles catering to the international market for the treatment of cancer, hormonal imbalances and other diseases. The facility is also designed to cater to the manufacturing needs of international pharmaceutical companies.
Commenting on the new facility, Satish Reddy, MD and chief operating officer, the company's said, "Our organization's multi-disciplinary capabilities have enabled our rapid growth in the pharmaceutical industry. The new facility is benchmarked to the highest global regulatory standards and is designed to cater to a global market that requires the most stringent standards of quality. We strongly believe that this unit will be one of the drivers of quantum growth for Dr Reddy's."
The plant has an in-built capacity-expansion capability, keeping in mind the company's product pipeline and global market trends. The plant has a production capacity of manufacturing 40 million Cytotoxic OSD capsules, 40 million Anti Hormonal formulations and 7 million injectibles per annum.
Speaking on the occasion, Ashwani Kumar Malhotra, executive vice president, formulations technical operations of the company's said, "With the setting up of this new unit, our key focus is to use the most advanced techniques and our large pool of scientific talent, coupled with superior process R&D skills for rapid process development. This facility, fully equipped with state-of-the-art infrastructure, will give us a competitive edge."
The unit has been designed to handle potent compounds using isolation technology, with equipment like a fully automated injectible filling line, single pot processors and wash-in-place tablet presses. The new facility represents a significant advance in technical sophistication over the company's other FTO facilities, of which 3 are located in Hyderabad, 1 in Yanam near Kakinada and 1 in Baddi, Himachal Pradesh. Its manufacturing facilities have been inspected by some of the world's most stringent regulatory authorities, including US FDA, MHA, MCC, and ANVISA.